ASR Vermogensbeheer N.V. Acquires New Shares in Gilead Sciences, Inc. (NASDAQ:GILD)

Key Points

• ASR Vermogensbeheer N.V. has acquired a new stake in Gilead Sciences, purchasing 104,313 shares valued at approximately $11.7 million during the first quarter.
• Insider sales recently occurred, with CFO Andrew D. Dickinson selling 2,500 shares and Director Jeffrey Bluestone selling 5,000 shares, contributing to a total of 82,000 shares sold by insiders in the past three months.
• Gilead Sciences has received positive analyst attention with multiple firms adjusting their price targets, including Needham & Company raising their target to $133.00 and Morgan Stanley to $135.00.

ASR Vermogensbeheer N.V. bought a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 104,313 shares of the biopharmaceutical company's stock, valued at approximately $11,688,000.

Other hedge funds also recently added to or reduced their stakes in the company. Smallwood Wealth Investment Management LLC acquired a new position in Gilead Sciences during the 1st quarter worth $25,000. Goodman Advisory Group LLC acquired a new position in shares of Gilead Sciences during the first quarter valued at $29,000. Core Alternative Capital increased its holdings in shares of Gilead Sciences by 370.8% during the first quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock valued at $34,000 after purchasing an additional 241 shares during the period. IMA Advisory Services Inc. bought a new stake in shares of Gilead Sciences during the first quarter valued at about $39,000. Finally, Clearstead Trust LLC lifted its holdings in Gilead Sciences by 287.6% in the first quarter. Clearstead Trust LLC now owns 376 shares of the biopharmaceutical company's stock worth $42,000 after purchasing an additional 279 shares during the period. 83.67% of the stock is currently owned by institutional investors.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of the business's stock in a transaction that occurred on Tuesday, July 15th. The stock was sold at an average price of $111.03, for a total value of $277,575.00. Following the completion of the sale, the chief financial officer owned 162,610 shares of the company's stock, valued at approximately $18,054,588.30. The trade was a 1.51% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jeffrey Bluestone sold 5,000 shares of the stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $109.74, for a total value of $548,700.00. Following the completion of the transaction, the director owned 8,920 shares in the company, valued at $978,880.80. This represents a 35.92% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 82,000 shares of company stock valued at $8,984,175 in the last three months. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Stock Performance

GILD stock opened at $110.28 on Thursday. The stock has a market cap of $137.18 billion, a P/E ratio of 23.22, a P/E/G ratio of 0.71 and a beta of 0.33. The company has a debt-to-equity ratio of 1.16, a quick ratio of 1.23 and a current ratio of 1.37. The firm has a 50 day simple moving average of $110.76 and a 200 day simple moving average of $107.12. Gilead Sciences, Inc. has a 52 week low of $72.43 and a 52 week high of $119.96.

Wall Street Analysts Forecast Growth

GILD has been the topic of several research analyst reports. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 target price on the stock in a research note on Friday, July 25th. Oppenheimer lowered their price objective on shares of Gilead Sciences from $132.00 to $125.00 and set an "outperform" rating on the stock in a research note on Friday, April 25th. Cantor Fitzgerald assumed coverage on Gilead Sciences in a research report on Tuesday, April 22nd. They issued an "overweight" rating and a $125.00 target price for the company. Finally, Morgan Stanley lifted their price target on Gilead Sciences from $130.00 to $135.00 and gave the company an "overweight" rating in a research report on Friday, April 25th. Eight analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $112.36.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.